載入中
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
前收盤價
US$3.52
+US$0.05 · +1.44%
盤中時間採用ET。市場資料可能有所延遲。
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
日內區間
目前US$3.52
52週區間
目前US$3.52
盤中時間採用ET。市場資料可能有所延遲。
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
日內區間
目前US$3.52
52週區間
目前US$3.52
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 714.5萬 USD | 2598.3萬 USD | 2435.4萬 USD | 1521.6萬 USD | 112萬 USD |
| 銷貨成本 | 76萬 USD | 5405.4萬 USD | 5173.8萬 USD | 3399.7萬 USD | 1967萬 USD |
| 毛利 | 638.5萬 USD | −2807.1萬 USD | −2738.4萬 USD | −1878.1萬 USD | −1855萬 USD |
| 研究與開發 | 9096.3萬 USD | 5103萬 USD | 4892.9萬 USD | 3266.2萬 USD | 1967萬 USD |
| 銷售、一般及管理費用 | 2982.2萬 USD | 3674.9萬 USD | 4454.9萬 USD | 4017.6萬 USD | 1851.1萬 USD |
| 營業費用 | 1.21億 USD | 3938.7萬 USD | 4454.9萬 USD | 4390萬 USD | 9266.7萬 USD |
| 利息收入 | 623.1萬 USD | 392.5萬 USD | 640萬 USD | 239.8萬 USD | 1.3萬 USD |
| 利息支出 | — | 15.4萬 USD | 23.1萬 USD | 23萬 USD | 66.5萬 USD |
| 折舊和攤銷 | 7.9萬 USD | 19.3萬 USD | 16.9萬 USD | 15.9萬 USD | 10.5萬 USD |
| 營業利益 | −1.14億 USD | −6745.8萬 USD | −7193.3萬 USD | −6268.1萬 USD | −1.11億 USD |
| 淨利 | −2059.6萬 USD | −6369.1萬 USD | −6576.5萬 USD | −6051.3萬 USD | −1.1億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$8.33
上漲空間 136.65%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI403.14萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM371.76萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF204.23萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO84.16萬0.00%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC47.11萬0.04%13.17億 USD0.60%US$183+0.11%
OneAscent Enhanced Small and Mid Cap ETFOASC22.03萬0.23%9669.61萬 USD1.38%US$34.57+0.90%
Avantis U.S. Small Cap Equity ETFAVSC21.76萬0.01%30.82億 USD0.25%US$69.98+0.03%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC18.63萬0.02%10.45億 USD0.20%US$86.29+0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCOneAscent Enhanced Small and Mid Cap ETFOASCAvantis U.S. Small Cap Equity ETFAVSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
